| Infection and Tumour Antigen Cellular Therapy (NCT02895412) | University of Sydney | 2016-08-01 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858) | Constellation Pharmaceuticals | 2014-07-16 |
| Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML (NCT02140242) | Technische Universität Dresden | 2014-04-16 |
| A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia (NCT01756118) | Goethe University | 2012-06-01 |
| Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) (NCT01339910) | Medical College of Wisconsin | 2011-06-01 |
| Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit (NCT01050946) | Medical College of Wisconsin | 2009-07-01 |
| Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) (NCT00406393) | Medical College of Wisconsin | 2006-11-01 |
| Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor (NCT00393380) | The Emmes Company, LLC | 2006-09-01 |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients (NCT00446303) | Groupe Francophone des Myelodysplasies | 2006-07-01 |
| Use of the MiCK Assay for Apoptosis in AML (NCT00286845) | Pierian Biosciences | 2006-01-01 |
| Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) (NCT00201240) | National Heart, Lung, and Blood Institute (NHLBI) | 2005-06-01 |
| Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) (NCT00126321) | University Hospital, Bonn | 2004-11-01 |
| Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia (NCT00152594) | University of Cologne | 2004-10-01 |
| Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) (NCT01723657) | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | 2003-10-01 |
| Randomized Double Cord Blood Transplant Study (NCT00067002) | M.D. Anderson Cancer Center | 2003-04-01 |
| Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia (NCT00136084) | St. Jude Children's Research Hospital | 2002-08-01 |
| Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) (NCT00044486) | Merck Sharp & Dohme LLC | 2002-07-01 |
| Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission (NCT00962767) | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-05-01 |
| Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia (NCT00304447) | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-04-01 |
| Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes (NCT00048100) | M.D. Anderson Cancer Center | 2001-02-01 |
| Risk-adapted Therapy for Adult Acute Myeloid Leukemia. (NCT01716793) | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | 1998-09-01 |
| Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia (NCT00251368) | Dana-Farber Cancer Institute | 1995-01-01 |
| Trial to Reduce Alloimmunization to Platelets (TRAP) (NCT00000589) | National Heart, Lung, and Blood Institute (NHLBI) | 1989-08-01 |